HER2 Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019

Heather Parsons, MD, MPH, and Ian Krop, MD, PhD, discuss advances in research and treatment for patients with HER2+ metastatic breast cancer. New therapies for HER2+ breast cancer, which accounts for about 20% of all breast cancer cases, are arriving at a faster clip than for any other type of cancer. Drs. Parsons and Krop provide an overview of ongoing studies testing antibody-drug conjugates that deliver chemotherapy directly to cancer cells, drugs that block the cell growth signal transmitted by HER2, and immunotherapies that aid the body’s “natural killer” cells. For more information about clinical trials for metastatic breast cancer, please visit https://www.dana-farber.org/metastati... This information was presented at the EMBRACE Metastatic Breast Cancer Forum at Dana-Farber in October 2019. EMBRACE (Ending Metastatic Breast Cancer for Everyone) is a Dana-Farber Cancer Institute program designed to offer metastatic breast cancer patients the best care possible by combining our expertise in clinical care and clinical research. As part of the program, our patients are offered a variety of supportive care resources and presented with emerging clinical trial opportunities in a personalized and ongoing basis. If you live a distance away, our care team can also collaborate with you and your local oncologist during your treatment. Near or far, we are here to provide active, continuous care to help you achieve the highest possible quality of life and make informed decisions about your care. For more information about the EMBRACE Program, please visit https://www.dana-farber.org/metastati...